Argenx
 | |
| Headquarters | , Belgium  |
|---|---|
Key people | |
| Revenue | 2,143,000,000 euro (2024) |
| 792,700,000 euro (2024) | |
| Website | argenx |
Argenx SE (Euronext: ARGX) is a Dutch biopharmaceutical company.
The company has been a member of the EURO STOXX 50 since 22 September 2025.[2]
Products
[edit]In April 2025, the US FDA approved a prefilled syringe version of the company's immune disorder drug Vyvgart.[3]
References
[edit]- ^ "Management Team". Argenx. Retrieved 18 November 2025.
- ^ "Euro Stoxx 50 Adds Deutsche Bank, Siemens Energy, Argenx". Morningstar. 2 September 2025. Retrieved 18 November 2025.
- ^ "US FDA approves syringe version of Argenx's immune disorder drug". Reuters. Archived from the original on 13 April 2025. Retrieved 18 November 2025.
